Novel panaxadiol triazole derivatives induce apoptosis in HepG-2 cells through the mitochondrial pathway
Shengnan Xiao1, Xude Wang1, Lei Xu1
1School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Abstract:
In this study, we introduced 1, 2, 4-triazole groups into panaxadiol (PD) to obtain 18 panaxadiol triazole derivatives. Five cancer cells and one normal cell were evaluated for cytotoxicity by MTT assay. The results showed that most of the derivatives could inhibit cancer cell proliferation, and the anti-proliferative activity of compound A1 was the most significant. For HepG-2 cells, the IC50 value was 4.21 ± 0.54 μM, which was nearly 15 times higher than the activity of PD. Further studies showed that compound A1 could induce apoptosis in HepG-2 cells, and could enhance the expression of Cl-caspase-3, Cl-caspase-9 and Cl-PARP. Moreover, Western blot analysis showed that after treating HepG-2 cells with compound A1, the expression of p53 protein was increased and the ratio of Bax/Bcl-2 was gradually increased. The cytoplasmic Bax is then translocated to the mitochondria, causing the release of Cyt c protein. Therefore, the results indicate that compound A1 induces apoptosis through the mitochondrial pathway and can be used the potential to develop new anti-proliferative agents.
Insights
Panaxadiol triazole derivatives were synthesized, with compound A1 showing significant anti-cancer activity against HepG-2 cells by inducing apoptosis through the mitochondrial pathway.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cancer Biology
Background:
- Panaxadiol (PD) is a natural compound with potential therapeutic applications.
- Developing novel anti-cancer agents with improved efficacy is a critical area of research.
Purpose of the Study:
- To synthesize novel panaxadiol triazole derivatives.
- To evaluate the anti-proliferative activity of these derivatives against various cancer cell lines.
- To elucidate the mechanism of action of the most potent derivative.
Main Methods:
- Synthesis of 18 panaxadiol triazole derivatives.
- Cytotoxicity evaluation using MTT assay against five cancer cell lines and one normal cell line.
- Apoptosis induction studies, including Western blot analysis for key apoptotic markers (Cl-caspase-3, Cl-caspase-9, Cl-PARP, p53, Bax, Bcl-2) and cytochrome c release.
Main Results:
- Most synthesized derivatives exhibited anti-proliferative effects on cancer cells.
- Compound A1 demonstrated the most significant anti-proliferative activity, with an IC50 of 4.21 ± 0.54 μM against HepG-2 cells, approximately 15-fold more potent than PD.
- Compound A1 induced apoptosis in HepG-2 cells via the mitochondrial pathway, evidenced by increased Cl-caspase-3, Cl-caspase-9, Cl-PARP, p53 expression, altered Bax/Bcl-2 ratio, and cytochrome c release.
Conclusions:
- Compound A1, a novel panaxadiol triazole derivative, exhibits potent anti-proliferative activity against HepG-2 cells.
- The anti-cancer mechanism of compound A1 involves the induction of apoptosis through the mitochondrial pathway.
- Compound A1 holds potential as a lead compound for the development of new anti-cancer agents.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
01:17The Extrinsic Apoptotic Pathway
01:30Apoptosis